TELA Bio (TELA) Expected to Announce Quarterly Earnings on Tuesday

TELA Bio (NASDAQ:TELA) is anticipated to issue its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $18.5970 million for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

TELA Bio (NASDAQ:TELA) last announced its quarterly earnings results on Tuesday, March 24th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. The company had revenue of $20.87 million during the quarter, compared to analysts’ expectations of $21.04 million. TELA Bio had a negative return on equity of 433.58% and a negative net margin of 48.37%. On average, analysts expect TELA Bio to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

TELA Bio Price Performance

TELA stock traded up $0.10 during midday trading on Tuesday, reaching $1.19. 332,411 shares of the stock were exchanged, compared to its average volume of 196,760. The company has a debt-to-equity ratio of 8.82, a current ratio of 4.20 and a quick ratio of 3.59. The stock has a market capitalization of $53.24 million, a PE ratio of -1.43 and a beta of 1.30. TELA Bio has a 52 week low of $0.50 and a 52 week high of $2.20. The company has a fifty day moving average price of $0.73 and a 200 day moving average price of $0.98.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Piper Sandler cut their target price on shares of TELA Bio from $1.25 to $1.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 25th. Canaccord Genuity Group reduced their price target on shares of TELA Bio from $4.00 to $2.00 and set a “buy” rating for the company in a research report on Wednesday, March 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of TELA Bio in a research report on Tuesday, April 21st. Citizens Jmp reduced their target price on TELA Bio from $5.00 to $3.00 and set a “market outperform” rating for the company in a research report on Friday, March 27th. Finally, Lake Street Capital lowered their price target on TELA Bio from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Wednesday, March 25th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $2.20.

Hedge Funds Weigh In On TELA Bio

A number of institutional investors and hedge funds have recently modified their holdings of the company. XTX Topco Ltd purchased a new stake in shares of TELA Bio during the fourth quarter worth about $48,000. Renaissance Technologies LLC grew its holdings in TELA Bio by 101.4% during the 4th quarter. Renaissance Technologies LLC now owns 128,700 shares of the company’s stock valued at $152,000 after buying an additional 64,800 shares in the last quarter. Susquehanna International Group LLP lifted its holdings in shares of TELA Bio by 551.2% in the third quarter. Susquehanna International Group LLP now owns 85,763 shares of the company’s stock worth $128,000 after buying an additional 72,594 shares in the last quarter. Finally, Citadel Advisors LLC boosted its position in shares of TELA Bio by 161.3% during the third quarter. Citadel Advisors LLC now owns 35,281 shares of the company’s stock worth $53,000 after acquiring an additional 21,781 shares during the last quarter. 94.35% of the stock is currently owned by hedge funds and other institutional investors.

About TELA Bio

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.